Aslan Pharmaceuticals Pte. Ltd., of Singapore, appointed Andrew Howden an independent non-executive director. Howden is a senior pharmaceutical executive with almost 35 years of experience and has a strong track record in clinical research, business development and commercialisation. Most recently, he was CEO of Inova Pharmaceuticals Pty Ltd., of Thornleigh, Australia, which was acquired by Valeant Pharmaceuticals International Inc., of Laval, Quebec.